No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PROK ProKidney
- 2.730
- -0.240-8.08%
Close Jun 14 16:00 ET
- 2.909
- +0.179+6.56%
Post 19:48 ET
174.51MMarket Cap-4789P/E (TTM)
3.047High2.715Low443.19KVolume2.940Open2.970Pre Close1.27MTurnover1.02%Turnover RatioLossP/E (Static)63.92MShares13.51052wk High-0.16P/B118.70MFloat Cap1.12052wk Low--Dividend TTM43.48MShs Float14.190Historical High--Div YieldTTM11.18%Amplitude1.120Historical Low2.866Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
ProKidney Surges 18% Following Pricing of Upsized $130M Stock Offering
Express News | ProKidney Shares Down 1.7% Premarket After Co Announces Pricing of Upsized Public Offering
ProKidney Prices Upsized $130 Million Stock Offering
ProKidney (PROK) said late Tuesday it priced a $130 million underwritten public offering and a concurrent registered direct offering of about 53.7 million of its class A ordinary shares at $2.42 per s
ProKidney Plans to Use Proceeds for Clinical Trial Costs, R&D, Continued Investment, General Corporate Purposes >PROK
ProKidney Plans to Use Proceeds for Clinical Trial Costs, R&D, Continued Investment, General Corporate Purposes >PROK
ProKidney Prices Upsized $130M Public Offering, Concurrent Registered Direct Offering of Class A Shares at $2.42 Each>PROK
ProKidney Prices Upsized $130M Public Offering, Concurrent Registered Direct Offering of Class A Shares at $2.42 Each>PROK
ProKidney Offerings Are Expected to Close Around June 13 >PROK
ProKidney Offerings Are Expected to Close Around June 13 >PROK
Comments
$ProKidney(PROK.US$
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2
$ProKidney(PROK.US$ ProKidney Announces Proposed $125 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering
$ProKidney(PROK.US$ Reuters
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg